Schirmer, Markus Anton

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Bernhardt, M."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Koenig, A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:20:53Z"],["dc.date.available","2018-11-07T10:20:53Z"],["dc.date.issued","2016"],["dc.format.extent","75"],["dc.identifier.isi","000371353700239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41971"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","59"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Pharmacogenetics and Genomics"],["dc.bibliographiccitation.lastpage","71"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Haberl, M."],["dc.contributor.author","Suk, A."],["dc.contributor.author","Kamdem, L. K."],["dc.contributor.author","Klein, K."],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Nurnberg, P."],["dc.contributor.author","Zanger, Ulrich M."],["dc.contributor.author","Wojnowski, Leszek"],["dc.date.accessioned","2018-11-07T10:40:54Z"],["dc.date.available","2018-11-07T10:40:54Z"],["dc.date.issued","2006"],["dc.description.abstract","Cytochrome P450 3A enzymes (CYP3A) play a major role in the metabolism of steroid hormones, drugs and other chemicals, including many carcinogens. The individually variable CYP3A expression, which remains mostly unexplained, has been suggested to affect clinical phenotypes. We investigated the CYP3A locus in five ethnic groups. The degree of linkage disequilibrium (LD) differed among ethnic groups, but the most common alleles of the conserved LD regions were remarkably similar. Non-African haplotypes are few; for example, only four haplotypes account for 80% of common European Caucasian alleles. Large LD blocks of high frequencies were suggestive of selection. Accordingly, European Caucasian and Asian cohorts each contained a block of single nucleotide polymorphism (SN Ps) with very high P excess values. The overlap between these blocks in these two groups contained only two of the investigated 26 SNPs and one of them was the CYP3A4 1B allele. The region centromeric of CYP3A4 lB exhibited high haplotype homozygosity in European Caucasians as opposed to Africa n-Americans. CYP3A4 lB showed a moderate effect on CYP3A4 mRNA and protein expression, as well as on CYP3A activity assessed as (V)max of testosterone 6 beta-hydroxylation in a liver bank. Our data are consistent with a functional relevance of CYP3A4 1B and with selection against this allele in non-African populations. The elimination of CYP3A4 1B involved different parts of the CYP3A locus in European Caucasians and Asians. Because CYP3A4 is involved in the vitamin D metabolism, rickets may have been the underlying selecting factor. Pharmacogenetics and Genomics 16:59-71. (c) 2006 Lippincott Williams & Wilkins."],["dc.identifier.isi","000234277400008"],["dc.identifier.pmid","16344723"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46413"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1744-6872"],["dc.title","Genetic signature consistent with selection against the CYP3A4 1B allele in non-African populations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","385"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Basic Research in Cardiology"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Sag, Can Martin"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Neumann, Kay"],["dc.contributor.author","Opiela, Marie-Kristin"],["dc.contributor.author","Zhang, J."],["dc.contributor.author","Steuer, Felicia"],["dc.contributor.author","Sowa, Thomas"],["dc.contributor.author","Gupta, Shamindra"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Anderson, Mark E."],["dc.contributor.author","Shah, Ajay M."],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Maier, Lars S."],["dc.date.accessioned","2018-11-07T09:19:46Z"],["dc.date.available","2018-11-07T09:19:46Z"],["dc.date.issued","2013"],["dc.description.abstract","Ionizing radiation (IR) is an integral part of modern multimodal anti-cancer therapies. IR involves the formation of reactive oxygen species (ROS) in targeted tissues. This is associated with subsequent cardiac dysfunction when applied during chest radiotherapy. We hypothesized that IR (i.e., ROS)-dependently impaired cardiac myocytes' Ca handling might contribute to IR-dependent cardiocellular dysfunction. Isolated ventricular mouse myocytes and the mediastinal area of anaesthetized mice (that included the heart) were exposed to graded doses of irradiation (sham 4 and 20 Gy) and investigated acutely (after similar to 1 h) as well as chronically (after similar to 1 week). IR induced a dose-dependent effect on myocytes' systolic function with acutely increased, but chronically decreased Ca transient amplitudes, which was associated with an acutely unaltered but chronically decreased sarcoplasmic reticulum (SR) Ca load. Likewise, in vivo echocardiography of anaesthetized mice revealed acutely enhanced left ventricular contractility (strain analysis) that declined after 1 week. Irradiated myocytes showed persistently increased diastolic SR Ca leakage, which was acutely compensated by an increase in SR Ca reuptake. This was reversed in the chronic setting in the face of slowed relaxation kinetics. As underlying cause, acutely increased ROS levels were identified to activate Ca/calmodulin-dependent protein kinase II (CaMKII). Accordingly, CaMKII-, but not PKA-dependent phosphorylation sites of the SR Ca release channels (RyR2, at Ser-2814) and phospholamban (at Thr-17) were found to be hyperphosphorylated following IR. Conversely, ROS-scavenging as well as CaMKII-inhibition significantly attenuated CaMKII-activation, disturbed Ca handling, and subsequent cellular dysfunction upon irradiation. Targeted cardiac irradiation induces a biphasic effect on cardiac myocytes Ca handling that is associated with chronic cardiocellular dysfunction. This appears to be mediated by increased oxidative stress and persistently activated CaMKII. Our findings suggest impaired cardiac myocytes Ca handling as a so far unknown mediator of IR-dependent cardiac damage that might be of relevance for radiation-induced cardiac dysfunction."],["dc.identifier.doi","10.1007/s00395-013-0385-6"],["dc.identifier.isi","000324877000001"],["dc.identifier.pmid","24068185"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10300"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28721"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/51"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | A03: Bedeutung CaMKII-abhängiger Mechanismen für die Arrhythmogenese bei Herzinsuffizienz"],["dc.relation.issn","0300-8428"],["dc.relation.workinggroup","RG L. Maier (Experimentelle Kardiologie)"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Ionizing radiation regulates cardiac Ca handling via increased ROS and activated CaMKII"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2328"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Cancer Research"],["dc.bibliographiccitation.lastpage","2338"],["dc.bibliographiccitation.volume","70"],["dc.contributor.author","Hoffmann, Marion"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Kreuz, Markus"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Wojnowski, Leszek"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T08:45:02Z"],["dc.date.available","2018-11-07T08:45:02Z"],["dc.date.issued","2010"],["dc.description.abstract","NAD(P)H oxidase is a major endogenous source of reactive oxygen species (ROS). ROS may not only be involved in carcinogenesis but also in efficacy of chemotherapeutic agents like doxorubicin. By a comprehensive genotyping approach covering 48 genetic polymorphisms (single-nucleotide polymorphisms) in five subunits of phagocytic NAD(P) H oxidase, we asked whether they affect gene expression, enzymatic activity, and outcome of CHO(E) P chemotherapy. A highly consistent effect was observed for the CYBA 640A>G variant. In peripheral blood granulocytes of 125 healthy volunteers, the G allele of 640A>G was associated with lower NAD(P) H oxidase activity (P = 0.006). Moreover, the G allele was associated with lower mRNA and protein expression (both P = 0.02). Of clinical importance, the outcome of patients suffering from non-Hodgkin lymphoma and treated with CHO(E) P regimen was dependent on the CYBA 640A>G polymorphism. In an exploratory study (n = 401), carriers of 640GG had an event-free survival (EFS) risk ratio of 1.95 [95% confidence interval (95% CI), 1.31-2.90; P = 0.001] compared with 640AA. In a confirmatory set (n = 477), the risk ratios were 1.53 (1.04-2.25, P = 0.03). The complete set of 878 patients showed a relative risk of 1.72 (1.30-2.26) and 1.59 (1.14-2.21) for EFS and overall survival, respectively. Further molecular-biological experiments showed lower expression and reduced stability of transcripts with the G allele in lymphoblastoid cell lines. Transfection of allele-specific plasmids into HEK293 cells elicited lower activity for the G allele in a luciferase reporter gene construct. Thus, CYBA 640A>G was shown to be a functional polymorphism with possible consequences for patients receiving CHO(E) P chemotherapy and might have further implications for other ROS-mediated modalities. Cancer Res; 70(6); 2328-38. (C) 2010 AACR."],["dc.identifier.doi","10.1158/0008-5472.CAN-09-2388"],["dc.identifier.isi","000278485900020"],["dc.identifier.pmid","20215507"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20334"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","0008-5472"],["dc.title","A Functional Polymorphism in the NAD(P)H Oxidase Subunit CYBA Is Related to Gene Expression, Enzyme Activity, and Outcome in Non-Hodgkin Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3384"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Patzer, Christoph"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Possiel, Jacqueline"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.date.accessioned","2021-09-01T06:43:07Z"],["dc.date.available","2021-09-01T06:43:07Z"],["dc.date.issued","2021"],["dc.description.abstract","Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, n = 52) and younger patients (n = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved."],["dc.description.abstract","Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, n = 52) and younger patients (n = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved."],["dc.identifier.doi","10.3390/cancers13143384"],["dc.identifier.pii","cancers13143384"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89222"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-455"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Postoperative Radiochemotherapy Using Modern Radiotherapy Techniques in Elderly Patients with Head and Neck Squamous Cell Carcinoma: The Challenge of Weighing Up Benefits and Harms of Treatment Modalities in Clinical Practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","323"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","British Journal of Clinical Pharmacology"],["dc.bibliographiccitation.lastpage","335"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Vormfelde, Stefan Viktor"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Hagos, Yohannes"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Engelhardt, Sabine"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Burckhardt, Gerhard"],["dc.contributor.author","Nuernberg, Peter"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T09:17:38Z"],["dc.date.available","2018-11-07T09:17:38Z"],["dc.date.issued","2006"],["dc.description.abstract","Aims To investigate the association between torsemide renal clearance and genetic variation in the basolaterally expressed renal organic anion transporters OAT1 and OAT3 and in the luminally situated OAT4. Methods We analysed 22 polymorphisms in the OAT coding genes SLC22A6, SLC22A8 and SLC22A11 and their haplotypes and measured torsemide renal clearance in 95 healthy men. In addition, the effect of torsemide on the OAT-mediated transport was studied in vitro. Results In stably transfected HEK293 cells torsemide (100 mu m) inhibited the uptake by human OAT1, OAT3 and OAT4 by 63.1, 58.1 and 68.0%, respectively. Torsemide renal clearance ranged from 6.5 to 43.1 ml min(-1) with a log-normal distribution and a geometric mean of 15.6 ml min(-1) (15.0-16.1 +/- SEM). No clear outlier group was observed. AA carriers of the polymorphism rs11231809 in SLC22A11 had a torsemide renal clearance of 13.3 ml min(-1) (12.7-13.9) compared with 15.1 ml min(-1) (14.5-15.8) in AT and 18.0 ml min(-1) (16.7-19.5) in TT carriers (P = 0.002). The two most frequent haplotypes at SLC22A11 showed an association with torsemide renal clearance. Homozygous carriage of these two haplotypes resulted in renal clearances of 21.2 ml min(-1) (19.0-23.7) and 11.8 ml min(-1) (10.5-13.5), respectively. No association between reanl clearance and genetic variation in SLC22A6 or SLC22A8 was observed. Conclusions Genetic variation in the gene encoding the luminally expressed OAT4 rather than in the basolaterally expressed OATs may affect the renal clearance of torsemide."],["dc.identifier.doi","10.1111/j.1365-2125.2006.02655.x"],["dc.identifier.isi","000239694000011"],["dc.identifier.pmid","16934049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28213"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","0306-5251"],["dc.title","Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Mergler, Caroline Patricia Nadine"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T08:55:29Z"],["dc.date.available","2018-11-07T08:55:29Z"],["dc.date.issued","2011"],["dc.format.extent","49"],["dc.identifier.isi","000291236200133"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22914"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","TGFB1 Pro25 allele as a risk marker for higher-grade acute Organ toxicity (CTC >= Grad2) during neoadjuvant Chemoradiotherapy in patients with locally advanced Rectal cancer (UICC Stage II/III)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","557"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Human Mutation"],["dc.bibliographiccitation.lastpage","565"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Kulle, Bettina"],["dc.contributor.author","Schirmer, M"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Suk, A."],["dc.contributor.author","Becker, C."],["dc.contributor.author","Tzvetkov, Mladen"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Bickeböller, Heike"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Nürnberg, Peter"],["dc.contributor.author","Wojnowski, Leszek"],["dc.date.accessioned","2017-09-07T11:54:27Z"],["dc.date.available","2017-09-07T11:54:27Z"],["dc.date.issued","2005"],["dc.description.abstract","The prospect of SNP-based genomewide association analysis has been extensively discussed, but practical experiences remain limited. We performed an association study using a recently developed array of 11,555 SNPs distributed throughout the human genome. A total of 104 DNA samples were hybridized to these chips with an average call rate of 97% (range 85.3-98.6%). The resulting genomewide scans were applied to distinguish between carriers and noncarriers of 37 test variants, used as surrogates for monogenic disease traits. The test variants were not contained in the chip and had been determined by other methods. Without adjustment for multiple testing, the procedure detected 24% of the test variants, but the positive predictive value was low (2%). Adjustment for multiple testing eliminated most false-positive associations, but the share of true positive associations decreased to 10-12%. We also simulated fine-mapping of susceptibility loci by restricting testing to the immediate neighborhood of test variants (+/- 5 Mb). This increased the proportion of correctly identified test variants to 22-27%. Simulation of a bigenic inheritance reduced the sensitivity to 1%. Similarly adverse effect had reduction of allelic penetrance. In summary, we demonstrate the feasibility and considerable specificity of SNP array based association studies to detect variants underlying monogenic, highly penetrant traits. The outcome is affected by allelic frequencies of chip SNPs, by the ratio between simulated \"cases\" and \"controls,\" and by the degree of linkage disequilibrium. A major improvement is expected from raising the density of the SNP array. (c) 2005 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/humu.20174"],["dc.identifier.gro","3143839"],["dc.identifier.isi","000229456700007"],["dc.identifier.pmid","15880731"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1397"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley-liss"],["dc.relation.issn","1059-7794"],["dc.title","Application of genomewide SNP arrays for detection of simulated susceptibility loci"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","190"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, H."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Helms, C."],["dc.contributor.author","Frank, M. A."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T09:38:37Z"],["dc.date.available","2018-11-07T09:38:37Z"],["dc.date.issued","2014"],["dc.format.extent","90"],["dc.identifier.isi","000337052500218"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33101"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","20th Annual Congress of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.relation.issn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.title","Cytokinesis-block micronucleus cytome assay for in vivo and in vitro lymphocyte radiosensitivity in patients undergoing radiochemotherapy for locally advanced rectal cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2805"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Riebeling, Theresa"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Hubert, Laura"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.date.accessioned","2021-07-05T15:00:42Z"],["dc.date.available","2021-07-05T15:00:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.3390/cancers13112805"],["dc.identifier.pii","cancers13112805"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87886"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]